Terms: = Pancreatic cancer AND MSN, P26038, 4478, ENSG00000147065
18 results:
1. The inhibition of pancreatic cancer progression by K-Ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
2. Leveraging Coupling Effect-Enhanced Surface Plasmon Resonance of Ruthenium Nanocrystal-Decorated Mesoporous Silica Nanoparticles for Boosted Photothermal Immunotherapy.
Li P; Chen Z; Xia F; Wang N; Zhao J; Hu X; Zhu M; Yu S; Ling D; Li F
Adv Healthc Mater; 2023 Dec; 12(31):e2302111. PubMed ID: 37699592
[TBL] [Abstract] [Full Text] [Related]
3. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of pancreatic cancer.
Slapak EJ; El Mandili M; Brink MST; Kros A; Bijlsma MF; Spek CA
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445886
[TBL] [Abstract] [Full Text] [Related]
4. Nanoparticles loaded with circ_0086375 for suppressing the tumorigenesis of pancreatic cancer by targeting the miR-646/SLC4A4 axis.
Wang Y; Zhang M; Zhang L; Zhou M; Wang E
Clin Exp Metastasis; 2023 Feb; 40(1):53-67. PubMed ID: 36479657
[TBL] [Abstract] [Full Text] [Related]
5. Nanoparticle combination for precise stroma modulation and improved delivery for pancreatic cancer.
Tarannum M; Holtzman K; Dréau D; Mukherjee P; Vivero-Escoto JL
J Control Release; 2022 Jul; 347():425-434. PubMed ID: 35569588
[TBL] [Abstract] [Full Text] [Related]
6. A Space-Time Conversion Vehicle for Programmed Multi-Drugs Delivery into pancreatic Tumor to Overcome Matrix and Reflux Barriers.
Huo T; Zhang X; Qian M; Nie H; Liang D; Lin C; Yang Y; Guo W; Lächelt U; Huang R
Adv Sci (Weinh); 2022 Jul; 9(20):e2200608. PubMed ID: 35508899
[TBL] [Abstract] [Full Text] [Related]
7. Short-term Outcomes of "Difficult" Laparoscopic Liver Resection at Specialized Centers: Report From INSTALL (International Survey on Technical Aspects of Laparoscopic Liver Resection)-2 on 4478 Patients.
Ibuki S; Hibi T; Tanabe M; Geller DA; Cherqui D; Wakabayashi G;
Ann Surg; 2022 May; 275(5):940-946. PubMed ID: 32889884
[TBL] [Abstract] [Full Text] [Related]
8. Development of Mesoporous Silica Nanoparticles of Tunable Pore Diameter for Superior Gemcitabine Drug Delivery in pancreatic cancer Cells.
Saini K; Prabhuraj RS; Bandyopadhyaya R
J Nanosci Nanotechnol; 2020 May; 20(5):3084-3096. PubMed ID: 31635652
[TBL] [Abstract] [Full Text] [Related]
9. Ternary-Responsive Drug Delivery with Activatable Dual Mode Contrast-Enhanced in Vivo Imaging.
Ren S; Yang J; Ma L; Li X; Wu W; Liu C; He J; Miao L
ACS Appl Mater Interfaces; 2018 Sep; 10(38):31947-31958. PubMed ID: 30179443
[TBL] [Abstract] [Full Text] [Related]
10. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract] [Full Text] [Related]
11. Large-Pore Functionalized Mesoporous Silica Nanoparticles as Drug Delivery Vector for a Highly Cytotoxic Hybrid Platinum-Acridine Anticancer Agent.
Zheng Y; Fahrenholtz CD; Hackett CL; Ding S; Day CS; Dhall R; Marrs GS; Gross MD; Singh R; Bierbach U
Chemistry; 2017 Mar; 23(14):3386-3397. PubMed ID: 28122141
[TBL] [Abstract] [Full Text] [Related]
12. Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery.
Fu Q; Hargrove D; Lu X
Nanomedicine; 2016 Oct; 12(7):1951-1959. PubMed ID: 27151564
[TBL] [Abstract] [Full Text] [Related]
13. Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.
Gurka MK; Pender D; Chuong P; Fouts BL; Sobelov A; McNally MW; Mezera M; Woo SY; McNally LR
J Control Release; 2016 Jun; 231():60-7. PubMed ID: 26763377
[TBL] [Abstract] [Full Text] [Related]
14. Multifunctional mesoporous silica nanospheres with cleavable Gd(III) chelates as MRI contrast agents: synthesis, characterization, target-specificity, and renal clearance.
Vivero-Escoto JL; Taylor-Pashow KM; Huxford RC; Della Rocca J; Okoruwa C; An H; Lin W; Lin W
Small; 2011 Dec; 7(24):3519-28. PubMed ID: 22069305
[TBL] [Abstract] [Full Text] [Related]
15. Definition of MCN (mucinous cystic neoplasm of the pancreas) and a proposal for a new concept of MRN or msn (mucinous round or spherical neoplasm).
Kimura W; Nomura T; Mizutani M; Ma J; Hirai I; Fuse A
Hepatogastroenterology; 2007; 54(79):1954-6. PubMed ID: 18251136
[TBL] [Abstract] [Full Text] [Related]
16. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract] [Full Text] [Related]
17. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET.
Sahani DV; Kalva SP; Fischman AJ; Kadavigere R; Blake M; Hahn PF; Saini S
AJR Am J Roentgenol; 2005 Jul; 185(1):239-46. PubMed ID: 15972430
[TBL] [Abstract] [Full Text] [Related]
18. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract] [Full Text] [Related]
